XML 49 R38.htm IDEA: XBRL DOCUMENT v3.25.3
FAIR VALUE MEASUREMENTS - Additional Information (Details)
€ in Millions, $ in Millions
3 Months Ended 9 Months Ended
Sep. 30, 2025
USD ($)
Sep. 30, 2024
USD ($)
Sep. 30, 2025
USD ($)
Sep. 30, 2024
USD ($)
Dec. 31, 2024
USD ($)
Mar. 04, 2021
EUR (€)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]            
In-process research and development impairments $ 0 $ 1,750 $ 190 $ 4,180    
Immunomedics | Fair Value, Nonrecurring | Level 3 | Fair value            
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]            
Future royalties 1,000   1,000   $ 900  
Immunomedics | Fair Value, Nonrecurring | Level 3 | Carrying value            
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]            
Future royalties $ 1,100   $ 1,100   $ 1,100  
Maximum            
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]            
Foreign currency derivative contract maturities (in months) 18 months   18 months      
Maximum | MYR GmbH            
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]            
Contingent consideration liability | €           € 300